Irinotecan
Brand Name:
Camptosar
Manufacturer:
Pfizer
Indication
Indication:
To treat metastatic colorectal cancer (mCRC) and is most commonly used in combination with 5-fluorouracil and leucovorin as part of the FOLFIRI regimen, either as first-line treatment or after prior therapy. It may also be used as monotherapy after progression on fluoropyrimidine-based treatment and is included in the FOLFOXIRI regimen for selected fit patients with advanced disease. Its use is primarily limited to advanced or metastatic colorectal cancer and it is not routinely indicated in the adjuvant setting for early-stage colon cancer.
Specific CRC Subtype:
None
Stage:
IV
Therapy Line:
First-line, Third-line or later
Health Canada Approval:
Approved
pCPA Negotiation Status:
Reimbursed in:
AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)
New Search
